Navigation Links
AGI Dermatics Closes $5 Million Investment Round
Date:4/8/2008

Investment to Enable Further Expansion of Remergent Skincare Line

FREEPORT, N.Y., April 8, 2008 /PRNewswire/ -- AGI Dermatics, the biopharmaceutical company focused on the development and sale of skincare products utilizing DNA repair technology, announced today it closed a $5 million investment round led by existing investor Trevi Health Ventures and new investor Spring Mountain Capital.

The new capital is being used to fund the continued growth of the Remergent brand skincare, including the launch of four new products. The Remergent skincare line preserves and restores healthy skin utilizing DNA repair enzymes delivered to the skin through a proprietary liposome delivery system.

"We are gratified that our current investors have renewed their commitment to the growth of our company brand and are pleased that a significant new investor has joined us in our vision of the opportunity in dermatology and skincare in the coming years," said Daniel Yarosh, Ph.D., President of AGI Dermatics. "This investment provides us with a platform to expand the reach of our technology into the marketplace."

About AGI Dermatics

AGI Dermatics is the biopharmaceutical company that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system and its proprietary brand, Remergent(R). Advancing the link between science and beauty, the company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com


'/>"/>
SOURCE AGI Dermatics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System
2. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
3. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
4. Tryton Medical, Inc. Closes $14 Million Financing
5. CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services
6. AssureRx Closes Round of Funding to Commercialize Pharmacogenetic Test
7. Clarus Ventures Closes $660 Million Fund
8. Ocera Therapeutics Closes $35.5 Million Series C Financing
9. Sinovac Closes $9.75 Million Private Placement
10. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
11. Progentix Orthobiology B.V. Closes Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, ... webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured ... event is free and open to the public, but registration is required. , ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):